The levels of CD133 expression in advanced serous ovarian cancers do not were associated with chemoresistance and shorter overall survival; in contrast, the expression of another stem cell-associated marker, nestin, correlates with cisplatin-resistance and poor survival [265]. The gene discussed is PROM1; the disease is ovarian serous adenocarcinoma.